Trial · NCT01815840
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Percent Change From Baseline in the Number of Clinically Evident Basal Cell Carcinomas at Week 73 (After 72 Weeks of Treatment) | Baseline; Week 73 | Participants in the Intent-to-Treat analysis population (defined as all randomized participants) with available data were included in the analysis. The last observation carried forward method was used. | percent change | MEAN |
| SECONDARY | Percentage of Participants Who Discontinued Study Treatment Due to Tolerability Issues | Baseline to Week 73 | Intent-to-Treat Analysis Population, defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Mean Percent Change From Baseline in Total Size of Three Target Basal Cell Carcinoma Lesions in Individual Participants at Week 73 | Baseline; Week 73 | Participants in the Intent-to-Treat Analysis Population (defined as all randomized participants) with available data were included in the analysis. | percent change | MEAN |
| SECONDARY | Percentage of Participants With at Least 50% Reduction in the Number of Basal Cell Carcinomas at Week 73 | Baseline; Week 73 | Intent-to-Treat Analysis Population, defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With New Basal Cell Carcinomas at Week 73 | Baseline; Week 73 | Participants in the Intent-to-Treat Analysis Population (defined as all randomized participants) with available data were included in the analysis. | percentage of participants | NUMBER |
| SECONDARY | Percent Change in Total Number of Basal Cell Carcinomas Relative to Baseline at Week 85 (12 Weeks Following End of Treatment) (Recurrence Rate) | Baseline; Week 85 | Participants in the Intent-to-Treat Analysis Population (defined as all randomized participants) with available data were included in the analysis. | percent change | MEAN |
| SECONDARY | Percent Change in Total Number of Basal Cell Carcinomas Relative to Baseline at Week 97 (24 Weeks Following End of Treatment) (Recurrence Rate) | Baseline; Week 97 | Participants in the Intent-to-Treat Analysis Population (defined as all randomized participants) with available data were included in the analysis. | percent change | MEAN |
| SECONDARY | Percent Change in Total Number of Basal Cell Carcinomas Relative to Baseline at Week 125 (52 Weeks Following End of Treatment) (Recurrence Rate) | Baseline; Week 125 | Participants in the Intent-to-Treat Analysis Population (defined as all randomized participants) with available data were included in the analysis. | percent change | MEAN |
| SECONDARY | Percentage of Participants Experiencing Any Adverse Event | Up to 125 weeks | Safety Analysis Population: participants in the Intent-to-Treat Analysis Population (defined as all randomized participants) who received at least one dose of study treatment. | percentage of participants | NUMBER |
| SECONDARY | Percent Change From Baseline in the Skindex-16 Symptom Domain Score at Week 73 | Baseline; Week 73 | Participants in the Intent-to-Treat Analysis Population (defined as all randomized participants) with available data were included in the analysis. | percent change | MEAN |
| SECONDARY | Percent Change From Baseline in the Skindex-16 Emotion Domain Score at Week 73 | Baseline; Week 73 | Participants in the Intent-to-Treat Analysis Population (defined as all randomized participants) with available data were included in the analysis. | percent change | MEAN |
| SECONDARY | Percent Change From Baseline in the Skindex-16 Function Domain Score at Week 73 | Baseline; Week 73 | Participants in the Intent-to-Treat Analysis Population (defined as all randomized participants) with available data were included in the analysis. | percent change | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01815840/outcomes